<SEC-DOCUMENT>0001193125-22-095321.txt : 20220405
<SEC-HEADER>0001193125-22-095321.hdr.sgml : 20220405
<ACCEPTANCE-DATETIME>20220404191805
ACCESSION NUMBER:		0001193125-22-095321
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		17
CONFORMED PERIOD OF REPORT:	20220331
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Cost Associated with Exit or Disposal Activities
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20220405
DATE AS OF CHANGE:		20220404

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CATALYST BIOSCIENCES, INC.
		CENTRAL INDEX KEY:			0001124105
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				562020050
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-51173
		FILM NUMBER:		22804648

	BUSINESS ADDRESS:	
		STREET 1:		611 GATEWAY BLVD., SUITE 710
		CITY:			SOUTH SAN FRANCISCO
		STATE:			CA
		ZIP:			94080
		BUSINESS PHONE:		650-871-0761

	MAIL ADDRESS:	
		STREET 1:		611 GATEWAY BLVD., SUITE 710
		CITY:			SOUTH SAN FRANCISCO
		STATE:			CA
		ZIP:			94080

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	TARGACEPT INC
		DATE OF NAME CHANGE:	20000919
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d313223d8k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8" ?>
<html xmlns:dei="http://xbrl.sec.gov/dei/2021" xmlns:us-types="http://fasb.org/us-types/2021-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:cbio="http://www.catalystbiosciences.com/20220331" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns="http://www.w3.org/1999/xhtml">
<head>
<title>8-K</title>
<meta http-equiv="Content-Type" content="text/html" />
</head>
   <body><div style="display:none"> <ix:header> <ix:hidden> <ix:nonNumeric name="dei:AmendmentFlag" contextRef="duration_2022-03-31_to_2022-03-31">false</ix:nonNumeric> <ix:nonNumeric id="Hidden_dei_EntityCentralIndexKey" name="dei:EntityCentralIndexKey" contextRef="duration_2022-03-31_to_2022-03-31">0001124105</ix:nonNumeric> </ix:hidden> <ix:references> <link:schemaRef xlink:type="simple" xlink:href="cbio-20220331.xsd" xlink:arcrole="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase"></link:schemaRef> </ix:references> <ix:resources> <xbrli:context id="duration_2022-03-31_to_2022-03-31"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-03-31</xbrli:startDate> <xbrli:endDate>2022-03-31</xbrli:endDate> </xbrli:period> </xbrli:context> </ix:resources> </ix:header> </div> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <p style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p> <p style="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">UNITED STATES</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">SECURITIES AND EXCHANGE COMMISSION</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Washington, D.C. 20549</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:10pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">FORM <span style="white-space:nowrap"><ix:nonNumeric name="dei:DocumentType" contextRef="duration_2022-03-31_to_2022-03-31">8-K</ix:nonNumeric></span></p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:10pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">CURRENT REPORT</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Pursuant to Section 13 or 15(d)</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">of the Securities Exchange Act of 1934</p> <p style="margin-top:10pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Date of Report (Date of earliest event reported): <ix:nonNumeric name="dei:DocumentPeriodEndDate" contextRef="duration_2022-03-31_to_2022-03-31" format="ixt:datemonthdayyearen">March 31, 2022</ix:nonNumeric></p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:10pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityRegistrantName" contextRef="duration_2022-03-31_to_2022-03-31">CATALYST BIOSCIENCES, INC.</ix:nonNumeric></p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Exact name of registrant as specified in its charter)</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:34%"></td>
<td style="vertical-align:bottom"></td>
<td style="width:32%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:32%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" contextRef="duration_2022-03-31_to_2022-03-31" format="ixt-sec:stateprovnameen">Delaware</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><span style="white-space:nowrap"><ix:nonNumeric name="dei:EntityFileNumber" contextRef="duration_2022-03-31_to_2022-03-31">000-51173</ix:nonNumeric></span></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><span style="white-space:nowrap"><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" contextRef="duration_2022-03-31_to_2022-03-31">56-2020050</ix:nonNumeric></span></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(State or other jurisdiction</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">of incorporation)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Commission</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">File Number)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(IRS Employer</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Identification No.)</p></td></tr></table> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityAddressAddressLine1" contextRef="duration_2022-03-31_to_2022-03-31">611 Gateway Blvd</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressAddressLine2" contextRef="duration_2022-03-31_to_2022-03-31">Suite 710</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressCityOrTown" contextRef="duration_2022-03-31_to_2022-03-31">South San Francisco</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressStateOrProvince" contextRef="duration_2022-03-31_to_2022-03-31">CA</ix:nonNumeric> <ix:nonNumeric name="dei:EntityAddressPostalZipCode" contextRef="duration_2022-03-31_to_2022-03-31">94080</ix:nonNumeric></p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Address of principal executive offices)</p></td></tr></table> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:CityAreaCode" contextRef="duration_2022-03-31_to_2022-03-31">(650)</ix:nonNumeric> <span style="white-space:nowrap"><ix:nonNumeric name="dei:LocalPhoneNumber" contextRef="duration_2022-03-31_to_2022-03-31">871-0761</ix:nonNumeric></span></p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Registrant&#8217;s telephone number, including area code)</p> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Not Applicable</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Former name or former address, if changed since last report.)</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below if the Form <span style="white-space:nowrap">8-K</span> filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top"><ix:nonNumeric name="dei:WrittenCommunications" contextRef="duration_2022-03-31_to_2022-03-31" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top"><ix:nonNumeric name="dei:SolicitingMaterial" contextRef="duration_2022-03-31_to_2022-03-31" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Soliciting material pursuant to Rule <span style="white-space:nowrap">14a-12</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.14a-12)</span></p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top"><ix:nonNumeric name="dei:PreCommencementTenderOffer" contextRef="duration_2022-03-31_to_2022-03-31" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="white-space:nowrap">Pre-commencement</span> communications pursuant to Rule <span style="white-space:nowrap">14d-2(b)</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.14d-2(b))</span></p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top"><ix:nonNumeric name="dei:PreCommencementIssuerTenderOffer" contextRef="duration_2022-03-31_to_2022-03-31" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="white-space:nowrap">Pre-commencement</span> communications pursuant to Rule <span style="white-space:nowrap">13e-4(c)</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.13e-4(c))</span></p></td></tr></table> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Securities registered pursuant to Section&#160;12(b) of the Act:</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:34%"></td>
<td style="vertical-align:bottom"></td>
<td style="width:32%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:32%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Title&#160;of&#160;each&#160;class</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Trading<br />Symbol(s)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Name&#160;of&#160;each&#160;exchange<br />on which&#160;registered</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:Security12bTitle" contextRef="duration_2022-03-31_to_2022-03-31">Common Stock</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:TradingSymbol" contextRef="duration_2022-03-31_to_2022-03-31">CBIO</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:SecurityExchangeName" contextRef="duration_2022-03-31_to_2022-03-31" format="ixt-sec:exchnameen">Nasdaq</ix:nonNumeric></span></td></tr></table> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167; 230.405 of this chapter) or Rule <span style="white-space:nowrap">12b-2</span> of the Securities Exchange Act of 1934 (&#167; <span style="white-space:nowrap">240.12b-2</span> of this chapter).</p> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Emerging growth company&#160;&#160;<ix:nonNumeric name="dei:EntityEmergingGrowthCompany" contextRef="duration_2022-03-31_to_2022-03-31" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></p> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a) of the Exchange Act.&#160;&#160;&#9744;</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p></div></div>

<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top" align="left"><span style="font-weight:bold">Item&#160;2.02</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Results of Operations and Financial Condition. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On March&#160;31, 2022, Catalyst Biosciences, Inc., (the &#8220;Company&#8221;) issued a press release announcing its financial results for the quarter ended December&#160;31, 2021. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form <span style="white-space:nowrap">8-K.</span> </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">The information set forth in this Item 2.02 (including Exhibit 99.1) is being furnished and shall not be deemed &#8220;filed&#8221; for purposes of Section&#160;18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), or the Exchange Act, regardless of any general incorporation language in such filing, except as expressly set forth by specific reference in such a filing. </span></p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top" align="left"><span style="font-weight:bold">Item&#160;2.05</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Costs Associated with Exit or Disposal Activities </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On March&#160;31, 2022, the Company announced that it is implementing expense reduction measures, including additional headcount reductions of approximately 19 employees, or approximately 70%. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As a result of the reduction in headcount, the Company estimates that it will incur up to approximately $0.8&#160;million in costs related to <span style="white-space:nowrap">one-time</span> severance costs and related expenses, which will all be incurred in the second quarter of 2022. The reduction in force is expected to be substantially completed by April&#160;30, 2022. The estimates of costs that the Company expects to incur and the timing thereof are subject to a number of assumptions and actual results may differ. The Company may also incur other charges or cash expenditures not currently contemplated due to events that may occur as a result of, or associated with, the decision to pivot from hemophilia to complement therapeutics and protease medicines platform. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Forward-Looking Statements </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This item 2.05 contains forward-looking statements that are intended to be covered by the safe harbor for &#8220;forward-looking statements&#8221; provided by the Private Securities Litigation Reform Act of 1995, as amended. Forward looking statements are statements that are not historical facts. Words such as &#8220;expects,&#8221; &#8220;believes,&#8221; &#8220;will,&#8221; &#8220;may,&#8221; &#8220;anticipates&#8221; and similar expressions are intended to identify forward-looking statements. These statements include, but are not limited to, statements regarding the anticipated benefits of the change in corporate strategy, the anticipated timing and details of the reduction in workforce and expected charges and costs associated with the reduction in workforce that the Company expects to incur. These statements are based on current expectations, estimates and projections about the Company&#8217;s business based, in part, on assumptions made by management, and are subject to a number of risks and uncertainties. Factors that could cause actual results to differ materially from current expectations include possible changes in the expected costs and charges associated with the reduction in force, and risks associated with the Company&#8217;s ability to achieve the expected benefits of the reduction in force and realignment of its resources. Additionally, these forward-looking statements should be considered in conjunction with the cautionary statements and risk factors described in the Company&#8217;s Annual Report on Form <span style="white-space:nowrap">10-K</span> for the year ended December&#160;31, 2021, and its other filings filed from time to time with the Securities and Exchange Commission. The Company does not assume any obligation to update any forward-looking statement, except as required by law. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top" align="left"><span style="font-weight:bold">Item&#160;5.02</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On March&#160;29, 2022, the Company amended its employment agreement with Seline Miller, the Company&#8217;s Senior Vice President of Finance and interim Chief Financial Officer, to provide that if Mrs.&#160;Miller&#8217;s employment is terminated without &#8220;cause&#8221; (as defined in the Employment Agreement) or as a result of &#8220;constructive termination&#8221; (as defined in the Employment Agreement), in each case outside of the &#8220;change in control protection period&#8221; (as defined in the Employment Agreement), Mrs.&#160;Miller would be eligible to receive, subject to certain conditions described in the Employment Agreement, her continued base salary for nine (9)&#160;months after the termination. </p>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, if Mrs.&#160;Miller&#8217;s employment is terminated without &#8220;cause&#8221; or as a result of &#8220;constructive termination,&#8221; in each case during the change in control protection period, Mrs.&#160;Miller would be eligible to receive, subject to certain conditions described in the Employment Agreement, severance payments, equal to the sum of (a) 100% of Mrs.&#160;Miller&#8217;s annual base salary and (b) 100% of Mrs.&#160;Miller&#8217;s maximum annual performance-based bonus, paid in equal installments for twelve (12)&#160;months after the termination. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The preceding description of the Employment Agreement is a summary and is qualified in its entirety by reference to the Original Employment Agreement and the Amendment to Original Employment Agreement, copies of which are filed as Exhibits 10.1 and 10.2, respectively, to this Current Report and incorporated herein by reference. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top" align="left"><span style="font-weight:bold">Item&#160;9.01</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Financial Statements and Exhibits. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(d) Exhibits </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td></td>

<td style="vertical-align:bottom;width:4%"></td>
<td style="width:93%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap" align="center"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:inline-block; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Exhibit<br />No.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:inline-block; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Description</p></td></tr>


<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">10.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d313223dex101.htm">Original Employment Agreement between Seline Miller and Catalyst Biosciences, Inc., dated November&#160;4, 2021. </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">10.2</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d313223dex102.htm">Amendment to Original Employment Agreement between Seline Miller and Catalyst Biosciences, Inc., effective as of March&#160;29, 2022. </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">99.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d313223dex991.htm">Press Release dated March&#160;31, 2022. </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">104</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Cover Page Interactive Data File (formatted as Inline XBRL document).</td></tr>
</table>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">SIGNATURES </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0">


<tr>

<td style="width:46%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:4%"></td>

<td style="vertical-align:bottom"></td>
<td style="width:2%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:45%"></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"><span style="font-weight:bold">CATALYST BIOSCIENCES, INC.</span></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"></td>
<td style="height:12pt" colspan="2"></td>
<td style="height:12pt" colspan="2"></td>
<td style="height:12pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Date: April&#160;4, 2022</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">&#160;&#160;&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Nassim Usman</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">Nassim Usman, Ph.D.</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">President and Chief Executive Officer</td></tr>
</table>
</div></div>

</body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>d313223dex101.htm
<DESCRIPTION>EX-10.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g313223g0405021300120.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:70%; font-size:10pt; font-family:Times New Roman">4&nbsp;November 2021 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Seline Miller </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">16050 Harwood Road </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Los Gatos, CA 95032 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dear Ms.&nbsp;Miller: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are pleased to confirm your promotion to the title of SVP, Finance of Catalyst Biosciences, Inc. (the &#147;<B>Company</B>&#148;) effective as of
October&nbsp;13, 2021 (the &#147;<B>Effective Date</B>&#148;). In this role, you will report directly to Nassim Usman, President&nbsp;&amp; Chief Executive Officer. As of the Effective Date, this letter agreement shall govern the terms of your
continued employment with the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">While employed by the Company, you agree to perform your duties faithfully and to the best of your abilities and
to devote your full business efforts and time to the Company. Except upon the prior written consent of the President&nbsp;&amp; CEO, you will not, during your employment with the Company, (i)&nbsp;accept any other employment, or (ii)&nbsp;engage,
directly or indirectly, in any other business activity (whether or not pursued for pecuniary advantage) that might interfere with your duties and responsibilities as SVP, Finance or create a conflict of interest with the Company. This consent will
not be unduly withheld by the President&nbsp;&amp; CEO. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Effective as of the Effective Date, your base compensation will be $25,000 per month ($300,000,
annualized), paid periodically in accordance with normal Company payroll practices and subject to the usual, required withholding. You will be eligible for a review of your salary in in connection with the regular review of executive salaries in
2022. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Effective as of the Effective Date, you will also have the opportunity to earn an annual performance-based bonus up to 30% of your annual salary.
To receive your bonus, you must be employed by the Company at the time the bonus is paid. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">During your employment with the Company, you will continue to
be eligible to participate in the Company&#146;s employee benefit plans including, but not limited to, Life, Disability, Medical, Dental and Vision Insurance, 401(k), Section&nbsp;125 Flexible Spending Accounts. The Company reserves the right to
cancel or change the benefit plans and programs it offers to its employees at any time. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As a full-time employee, you will continue to be eligible for
<FONT STYLE="white-space:nowrap">paid-time-off</FONT> benefits, for such things as sick leave, vacation time or time for personal needs, in accordance with our policies for similarly situated employees. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">You will be eligible to receive stock options or other equity compensation as determined from time to time by the Compensation Committee of the Board of
Directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the event your employment with us is terminated for any reason other than death or Disability (as defined in the relevant equity award
documentation), you will have three months following the termination of employment to exercise the vested portion of any option grant. In the event your employment with us is terminated due to your death or Disability, the vested portion of any
option grant may be exercised within the <FONT STYLE="white-space:nowrap">one-year</FONT> period following the termination of your employment. In no event may any option grant be exercised after the expiration of its
<FONT STYLE="white-space:nowrap">ten-year</FONT> term. You should be aware that your employment with the Company is for no specified period and constitutes &#147;at will&#148; employment. As a result, you are free to terminate your employment at any
time, for any reason or for no reason. Similarly, the Company is free to terminate your employment at any time, for any reason or for no reason. The <FONT STYLE="white-space:nowrap">at-will</FONT> employment policy can only be changed by a written
document approved by the Board and signed on behalf of the Board. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Should your employment with the Company be terminated without Cause or as a result of
Constructive Termination (each as defined below), in each case outside of the Change in Control Protection Period (as defined below), you shall be eligible to receive (i)&nbsp;severance payments, equal to the rate of base salary which you were
receiving at the time of such termination, during the period from the date of your termination until the date that is six (6)&nbsp;months after the effective date of the termination (the &#147;<B>Severance Period</B>&#148;), which payments shall be
paid during the Severance Period (or applicable shorter period) in accordance with the Company&#146;s standard payroll practice following the effective date of the release described below and which shall be subject to applicable withholding taxes,
(ii)&nbsp;accelerated vesting as of the time of such termination with respect to the unvested options held by you that would have vested during the Severance Period, and (iii)&nbsp;if you elect to continue your Company health insurance coverage
under the Consolidated Omnibus Budget Reconciliation Act (&#147;<B>COBRA</B>&#148;) following such termination, payment by the Company of the same portion of your monthly premium under COBRA as it pays for active employees until the earliest of
(a)&nbsp;the close of the Severance Period, (b)&nbsp;the expiration of your continuation coverage under COBRA or (c)&nbsp;the date when you become eligible for substantially equivalent health insurance coverage in connection with new employment or
self-employment. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Should your employment with the Company be terminated without Cause (as defined below) or as a result of
Constructive Termination, in each case during the six (6)&nbsp;month period prior to or the eighteen (18)&nbsp;month period following a Change in Control (as defined in the Company&#146;s 2018 Omnibus Incentive Plan, as amended from time to time)
(the &#147;<B>Change in Control Protection Period</B>&#148;), you shall be eligible to receive (i)&nbsp;severance payments, equal to the sum of (a) 75% of your annual base salary determined at the rate at which you were receiving your base salary at
the time of such termination and (b) 75% of your maximum annual performance-based bonus at the time of such termination, paid in equal installments during the period from the date of the termination until the date that is nine (9)&nbsp;months after
the effective date of the termination (the &#147;<B><FONT STYLE="white-space:nowrap">Post-COC</FONT> Severance Period</B>&#148;), which payments shall be paid during the <FONT STYLE="white-space:nowrap">Post-COC</FONT> Severance Period (or
applicable shorter period) in accordance with the Company&#146;s standard payroll practice following the effective date of the release described below and which shall be subject to applicable withholding taxes, (ii) 100% percent of any unvested
options held by you will vest as of the time of such termination, and (iii)&nbsp;if you elect to continue your Company health insurance coverage under COBRA following such termination, payment by the Company of the same portion of your monthly
premium under COBRA as it pays for active employees until the earliest of (a)&nbsp;the close of the <FONT STYLE="white-space:nowrap">Post-COC</FONT> Severance Period, (b)&nbsp;the expiration of your continuation coverage under COBRA or (c)&nbsp;the
date when you become eligible for substantially equivalent health insurance coverage in connection with new employment or self-employment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any severance
benefits under this letter agreement are conditioned upon your execution of a release of claims in a form provided by the Company, and any severance payments shall commence on the 60th day following your separation, so long as you have signed a
release that has become irrevocable during such period, with the initial payment including payments that otherwise would have been made during the sixty day period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Notwithstanding anything to the contrary in this letter agreement, any payment or benefit due to you under this letter agreement or otherwise will not be paid
or provided during the six (6)&nbsp;month period following your termination of employment if (i)&nbsp;the Company determines, in its good faith judgment, that you are a &#147;specified&#148; employee under Section&nbsp;409A of the Internal Revenue
Code and any treasury regulations and internal revenue service guidance thereunder (&#147;<B>Section</B><B></B><B>&nbsp;409A</B>&#148;) and (ii)&nbsp;such payments or benefits are &#147;nonqualified deferred compensation&#148; for purposes of
Section&nbsp;409A . If the payment of any amounts are delayed as a result of the previous sentence, any cash severance payments due to you pursuant to this letter agreement or otherwise during the first six (6)&nbsp;months after your termination
will accrue during such six month period and will become payable in a lump sum payment on the date six (6)&nbsp;months and one (1)&nbsp;day following the date of your termination. Thereafter, payments will resume in accordance with the applicable
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
schedule set forth in this letter agreement. You agree to work in good faith with the Company to consider amendments to this letter agreement which are necessary or appropriate to avoid
imposition of any additional tax or income recognition under Section&nbsp;409A prior to the actual payment to you of payments or benefits under this letter agreement. Notwithstanding the foregoing, this letter agreement will be deemed amended,
without any consent required from you, to the extent necessary to avoid imposition of any additional tax or income recognition pursuant to Section&nbsp;409A prior to actual payments to you under this letter agreement. You and the Company agree to
cooperate with each other and to take reasonably necessary steps in this regard. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This letter agreement is intended to comply with the requirements of
Section&nbsp;409A, including the exceptions thereto, and shall be construed and administered in accordance with such intent. Notwithstanding any other provision of this letter agreement, payments provided under this letter agreement may only be made
upon an event and in a manner that complies with Section&nbsp;409A or an applicable exemption. Any payments under this letter agreement that may be excluded from Section&nbsp;409A either as separation pay due to an involuntary separation from
service or as a short-term deferral shall be excluded from Section&nbsp;409A to the maximum extent possible. For purposes of Section&nbsp;409A, each installment payment provided under this letter agreement shall be treated as a separate payment. Any
payments to be made under this letter agreement in connection with a termination of employment shall only be made if such termination of employment constitutes a &#147;separation from service&#148; under Section&nbsp;409A. To the extent that
reimbursements or other <FONT STYLE="white-space:nowrap">in-kind</FONT> benefits under this letter agreement constitute &#147;nonqualified deferred compensation&#148; for purposes of Section&nbsp;409A, (i)&nbsp;such expenses or other reimbursements
hereunder shall be made on or prior to the last day of the taxable year following the taxable year in which such expenses were incurred, (ii)&nbsp;no right to such reimbursement or <FONT STYLE="white-space:nowrap">in-kind</FONT> benefits shall be
subject to liquidation or exchange for another benefit, and (iii)&nbsp;no such reimbursement, expenses eligible for reimbursement, or <FONT STYLE="white-space:nowrap">in-kind</FONT> benefits provided in any taxable year shall in any way affect the
expenses eligible for reimbursement, or <FONT STYLE="white-space:nowrap">in-kind</FONT> benefits to be provided, in any other taxable year. Notwithstanding the foregoing, the Company makes no representations that the payments and benefits provided
under this letter agreement comply with Section&nbsp;409A and in no event shall the Company, any Company affiliates, or their respective employees, officers, directors, agents and representatives (including, without limitation, legal counsel) be
liable for all or any portion of any taxes, penalties, interest or other expenses that may be incurred by you on account of <FONT STYLE="white-space:nowrap">non-compliance</FONT> with Section&nbsp;409A. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Cause</B>&#148; shall mean (i)&nbsp;your failure to perform your assigned duties or
responsibilities as an employee of the Company after notice thereof from the Company describing your failure to perform such duties or responsibilities, (ii)&nbsp;your engaging in any act of dishonesty, fraud or misrepresentation, (iii)&nbsp;your
violation of any federal or state law or regulation applicable to the Company&#146;s business, (iv)&nbsp;your breach of any confidentiality agreement or invention assignment agreement between you and the Company, or (v)&nbsp;your being convicted of
or entering a plea of <I>nolo contendere </I>to, any crime or committing any act of moral turpitude. The determination as to whether you are being terminated for Cause will be made in good faith by the Company and will be final and binding on you.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>&#147;Constructive Termination&#148; </B>shall be deemed to occur if, without your written consent, within 90 days following any of the conditions
below, you terminate your employment in accordance with this provision: (A)&nbsp;the Company&#146;s material breach of this letter agreement resulting from the failure of the Company to require any successor to the Company upon a Change in Control
to assume the Company&#146;s obligations under this letter agreement, (B)&nbsp;a material reduction in your job duties or responsibilities inconsistent with your position with the Company and prior duties or responsibilities , provided that neither
(a)&nbsp;the loss of an &#147;interim&#148; position and your reassignment to a position substantially similar to your role prior to such interim position, whether before or after a Change in Control or (b)&nbsp;a mere change in title alone nor
reassignment following a Change in Control to a position that is substantially similar to the position held prior to the Change in Control in terms of job duties or responsibilities shall constitute a material reduction in job responsibilities, or
(C)&nbsp;the request by the Company or its successor to relocate the principal place for performance of your Company duties to a location more than thirty (30)&nbsp;miles from your then-current principal business location; provided that (i)&nbsp;you
have provided written notice of your intent to terminate employment on the basis of a Constructive Termination within sixty (60)&nbsp;days after the Constructive Termination condition first occurs, and (ii)&nbsp;the Company fails to correct the
Constructive Termination within thirty (30)&nbsp;days after receipt of your written notice. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the event that the severance and other payments or
benefits provided for in this letter agreement or otherwise payable to you (i)&nbsp;constitute &#147;parachute payments&#148; within the meaning, of Section&nbsp;280G of the Code, and (ii)&nbsp;but for this paragraph would be subject to the excise
tax imposed by Section&nbsp;4999 of the Code (the &#147;<B>Excise Tax</B>&#148;), then your benefits under this letter agreement shall be either </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">delivered in full, or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">B.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">delivered as to such lesser extent which would result in no portion of such benefits being subject to the
Excise Tax, </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">whichever of the foregoing amounts, taking into account the applicable federal, state and local income taxes and the Excise
Tax, results in the receipt by you on an <FONT STYLE="white-space:nowrap">after-tax</FONT> basis, of the greatest amount of benefits, notwithstanding that all or some portion of such benefits may be taxable under Section&nbsp;4999 of the Code. If a
reduction is </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
required and no parachute payments constitute nonqualified deferred compensation under Section&nbsp;409A, you shall be able to select which payments and/or benefits are reduced and the order of
reduction. If a reduction is required and any parachute payments constitute nonqualified deferred compensation under Section&nbsp;409A, the reduction shall occur in the following order: (i)&nbsp;options whose exercise price exceeds the fair market
value of the optioned equity, (ii)&nbsp;Full Credit Payments (as defined below) that are payable in cash, <FONT STYLE="white-space:nowrap">(iii)&nbsp;non-cash</FONT> Full Credit Payments that are taxable,
<FONT STYLE="white-space:nowrap">(iv)&nbsp;non-cash</FONT> Full Credit Payments that are not taxable (v)&nbsp;Partial Credit Payments (as defined below) and <FONT STYLE="white-space:nowrap">(vi)&nbsp;non-cash</FONT> employee welfare benefits. In
each case, reductions shall be made in reverse chronological order such that the payment or benefit owed on the latest date following the occurrence of the event triggering the excise tax will be the first payment or benefit to be reduced (with
reductions made <FONT STYLE="white-space:nowrap">pro-rata</FONT> in the event payments or benefits are owed at the same time). The term &#147;Full Credit Payment&#148; means a payment or benefit that if reduced in value by one dollar reduces the
amount of the parachute payment (as defined in Section&nbsp;280G of the Code) by one dollar. &#147;Partial Credit Payment&#148; means any payment or benefit that is not a Full Credit Payment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">You understand and agree that by accepting terms of this letter agreement, you represent to the Company that your performance will not breach any other
agreement to which you are a party and that you have not, and will not during the term of your employment with the Company, enter into any oral or written agreement in conflict with any of the provisions of this letter or the Company&#146;s
policies. You are not to bring with you to the Company, or use or disclose to any person associated with the Company, any confidential or proprietary information belonging to any former employer or other person or entity with respect to which you
owe an obligation of confidentiality under any agreement or otherwise. The Company does not need and will not use such information. Also, we expect you to abide by any obligations to refrain from soliciting any person employed by or otherwise
associated with any former employer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This letter agreement and the confidential information and/or inventions assignment agreement between you and the
Company represent the entire agreement and understanding between you and the Company concerning your employment relationship with the Company and supersede in their entirety any and all prior agreements and understandings concerning your employment
relationship with the Company, whether written or oral. Except as specifically provided in this letter agreement, this letter agreement can only be amended in a writing approved by the Board and signed by you and a duly authorized officer of the
Company. Any waiver of a right under this letter agreement must be in writing. The Company will require any successor to all or substantially all of its assets or businesses to assume this letter agreement and perform the Company&#146;s obligations
hereunder. This letter agreement will be governed by California law. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Seline, we appreciate your valuable contributions to Catalyst and look forward to your continued
participation in the Company&#146;s future success! </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Sincerely, </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">/s/ Nassim Usman</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Nassim Usman, Ph.D.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">President&nbsp;&amp; Chief Executive Officer</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Accepted and agreed to this </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Nov 7, 2021 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Seline Miller</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Seline Miller</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>3
<FILENAME>d313223dex102.htm
<DESCRIPTION>EX-10.2
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.2</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.2 </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>AMENDMENT TO EMPLOYMENT AGREEMENT</U> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">THIS AMENDMENT TO THE EMPLOYMENT AGREEMENT (this &#147;<B><I>Amendment</I></B>&#148;) is made effective as of March&nbsp;29, 2022 (the
&#147;<B><I>Effective Date</I></B>&#148;) between Catalyst Biosciences, Inc., a Delaware corporation (the &#147;<B><I>Company</I></B>&#148;), and Seline Miller (&#147;<B><I>Employee</I></B>&#148;). </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>RECITALS </U></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>,
Employee and the Company previously entered into an Employment Agreement dated November&nbsp;4, 2021 (the &#147;<B><I>Employment Agreement</I></B>&#148;); </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>, the Company desires to amend the terms of the Employment Agreement to modify the terms of Employee&#146;s severance benefits
(collectively, the &#147;<B><I>Modifications</I></B>&#148;); and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>, Employee has agreed to the Modifications. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>NOW, THEREFORE</B>, in consideration of the promises and mutual covenants contained herein, and intending to be legally bound hereby, the
parties agree that the Employment Agreement is amended as follows: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.</B> <B><U>Base Compensation and Bonus Adjustment</U></B>. The
third and fourth paragraphs of the Employment Agreement are hereby deleted in their entirety and replaced with the following: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;Effective as of January&nbsp;1, 2022, your base compensation will be $27,083.33 per month ($325,000 annualized), paid periodically in
accordance with normal Company payroll practices and subject to the usual, required withholding. You will be eligible for a review of your salary in connection with regular review of executive salaries in 2023. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Beginning with respect to the Company&#146;s 2022 fiscal year, you will also have the opportunity to earn an annual performance-based bonus up
to 40% of your annual salary. To receive your bonus, you must be employed by the Company at the time the bonus is paid.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.</B>
<B><U>Severance Period and <FONT STYLE="white-space:nowrap">Post-COC</FONT> Severance Period Adjustments</U></B>. The ninth paragraph of the Employment Agreement is hereby deleted in its entirety and replaced with the following: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;Should your employment with the Company be terminated without Cause or as a result of Constructive Termination (each as defined below),
in each case outside of the Change in Control Protection Period (as defined below), you shall be eligible to receive (i)&nbsp;severance payments, equal to the rate of base salary which you were receiving at the time of such termination, during the
period from the date of your termination until the date that is nine (9)&nbsp;months after the effective date of the termination (the &#147;<B>Severance Period</B>&#148;), which payments shall be paid during the Severance Period (or applicable
shorter period) in accordance with the Company&#146;s standard payroll practice following the effective date of the release described below and which shall be subject to applicable withholding taxes, (ii)&nbsp;accelerated vesting as of the time of
such termination with respect to the unvested options held by you that would have vested during the Severance Period, and (iii)&nbsp;if you elect to continue your Company health insurance coverage under the Consolidated Omnibus Budget Reconciliation
Act </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
(&#147;<B>COBRA</B>&#148;) following such termination, payment by the Company of the same portion of your monthly premium under COBRA as it pays for active employees until the earliest of
(a)&nbsp;the close of the Severance Period, (b)&nbsp;the expiration of your continuation coverage under COBRA or (c)&nbsp;the date when you become eligible for substantially equivalent health insurance coverage in connection with new employment or
self-employment.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3.</B> <B><U><FONT STYLE="white-space:nowrap">Post-COC</FONT> Severance Adjustment</U></B>. The tenth paragraph
of the Employment Agreement is hereby deleted in its entirety and replaced with the following: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;Should your employment with the
Company be terminated without Cause (as defined below) or as a result of Constructive Termination, in each case during the six (6)&nbsp;month period prior to or the eighteen (18)&nbsp;month period following a Change in Control (as defined in the
Company&#146;s 2018 Omnibus Incentive Plan, as amended from time to time) (the &#147;<B>Change in Control Protection Period</B>&#148;), you shall be eligible to receive (i)&nbsp;severance payments, equal to the sum of (a) 100% of your annual base
salary determined at the rate at which you were receiving your base salary at the time of such termination and (b) 100% of your maximum annual performance-based bonus at the time of such termination, paid in equal installments during the period from
the date of the termination until the date that is twelve (12)&nbsp;months after the effective date of the termination (the &#147;<B><FONT STYLE="white-space:nowrap">Post-COC</FONT> Severance Period</B>&#148;),<B> </B>which payments shall be paid
during the <FONT STYLE="white-space:nowrap">Post-COC</FONT> Severance Period (or applicable shorter period) in accordance with the Company&#146;s standard payroll practice following the effective date of the release described below and which shall
be subject to applicable withholding taxes, (ii) 100% percent of any unvested options held by you will vest as of the time of such termination, and (iii)&nbsp;if you elect to continue your Company health insurance coverage under COBRA following such
termination, payment by the Company of the same portion of your monthly premium under COBRA as it pays for active employees until the earliest of (a)&nbsp;the close of the <FONT STYLE="white-space:nowrap">Post-COC</FONT> Severance Period,
(b)&nbsp;the expiration of your continuation coverage under COBRA or (c)&nbsp;the date when you become eligible for substantially equivalent health insurance coverage in connection with new employment or self-employment.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>4.</B> <B><U>No Other Modification</U></B>. Except as provided herein, the provisions of the Employment Agreement shall remain in full
force and effect following the adoption of this Amendment and this Amendment shall not constitute a modification or waiver of any provision of the Employment Agreement except as provided herein. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.</B> <B><U>Governing Law</U></B>. This Amendment shall be construed under and be governed by California law without giving effect to
California conflict of laws principles. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>[Signature Page Follows] </I></B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF</B>, the parties hereto have duly executed this Amendment as of the
date first above written. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>CATALYST BIOSCIENCES, INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Nassim Usman</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By: Nassim Usman, Ph.D.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title: President&nbsp;&amp; Chief Executive Officer</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>EMPLOYEE</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Seline Miller</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Seline Miller</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>[Signature Pages to Amendment] </I></B></P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>4
<FILENAME>d313223dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g313223dsp001.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Catalyst Biosciences Reports Fourth Quarter and <FONT STYLE="white-space:nowrap">Year-end</FONT> 2021
Operating&nbsp;&amp; Financial </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Results and Provides a Corporate Update </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SOUTH SAN FRANCISCO, Calif. &#150; March</B><B></B><B>&nbsp;31, 2022</B> &#150; Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced its operating and
financial results for the fourth quarter and year ended December&nbsp;31, 2021 and provided a corporate update. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;In late 2021 we announced a
strategic change in corporate strategy, pivoting from hemophilia to a highly promising complement therapeutics and protease medicines platform,&#148; said Nassim Usman, Ph.D., president and chief executive officer of Catalyst. &#147;This month, we <FONT
STYLE="white-space:nowrap">re-acquired</FONT> the full rights to CB <FONT STYLE="white-space:nowrap">2782-PEG</FONT> adding to our promising portfolio, which includes CB 4332 our enhanced CFI development candidate. Having the full rights to these
two potentially <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">best-in-class</FONT></FONT> candidates in dry AMD provides another opportunity in our exploration of strategic alternatives that was announced in February. We are also
implementing expense reduction measures, including headcount, while we continue this process.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Recent Milestones </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Regained the rights to CB <FONT STYLE="white-space:nowrap">2782-PEG</FONT> for the treatment of Dry AMD,
expanding the Company&#146;s complement portfolio in ophthalmology. With the full rights to CB <FONT STYLE="white-space:nowrap">2782-PEG</FONT> back under the company&#146;s control, Catalyst now has two wholly owned, potentially <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">best-in-class</FONT></FONT> development candidates. Dry AMD is a leading cause of blindness in its severe form for which there are no currently approved drugs. The potential dry AMD market
is estimated to be over $10&nbsp;billion. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Received Rare Pediatric Disease Designation for CB 4332 for the treatment of CFI Deficiency. Under the FDA&#146;s
rare pediatric disease designation program, the FDA may grant a priority review voucher to a sponsor that received product approval for a rare pediatric disease. A rare pediatric disease is defined as a serious or life-threatening condition that
affects less than 200,000 individuals in the U.S. per year and who are primarily less than 18 years of age. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Announced plans to explore strategic alternatives for the company. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Implemented further personnel and cost reductions, including additional headcount reductions of approximately 19
employees, or 70%, that are expected to be completed by April&nbsp;30, 2022. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Fourth Quarter and
<FONT STYLE="white-space:nowrap">Year-End</FONT> 2021 Results and Financial Highlights </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Cash, cash equivalents, and, investments, as of December&nbsp;31, 2021, were $46.9&nbsp;million.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Research and development expense for the three months and year ended December&nbsp;31, 2021 was
$16.1&nbsp;million and $68.9&nbsp;million respectively, compared with $14.6&nbsp;million and $53.0&nbsp;million for the prior year periods, respectively. The increase was due primarily to an increase in MarzAA clinical and manufacturing costs,
preclinical research costs, personnel-related costs including <FONT STYLE="white-space:nowrap">one-time</FONT> severance costs associated with our restructuring, and an increase in facilities costs. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">General and administrative expense for the three months and year ended December&nbsp;31, 2021 was
$4.2&nbsp;million and $19.0&nbsp;million, respectively, compared with $4.3&nbsp;million and $16.2&nbsp;million, for the prior year periods, respectively. This increase was due primarily to an increase in personnel-related costs and an increase in
professional services. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g313223dsp001.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Interest and other income (expense), net for the three months and year ended December&nbsp;31, 2021 was $(16,000)
and $(39,000) respectively, compared with $(0.1) million and $1.1&nbsp;million, for the prior year periods, respectively. The $1.2&nbsp;million decrease was primarily due to a decrease in interest income and due to the payment received in the first
quarter of 2020 under an agreement associated with neuronal nicotinic receptor asset sold in 2016. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Net loss attributable to common stockholders for the three months and year ended December&nbsp;31, 2021 was
$20.3&nbsp;million, or ($0.65) per basic and diluted share, and $87.9&nbsp;million, or ($2.87) per basic and diluted share, respectively, compared with $18.9&nbsp;million, or ($0.86) per basic and diluted share, and $56.2&nbsp;million, or ($2.93)
per basic and diluted share, for the prior year periods, respectively. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">As of December&nbsp;31, 2021, the Company had 31,409,707 shares of common stock outstanding.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Catalyst Biosciences, the Protease Medicines company </B> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Catalyst is a research and clinical development biopharmaceutical company focused on developing protease therapeutics to address unmet medical needs in
disorders of the complement system. Proteases are natural regulators of this biological system. We engineer proteases to create improved or novel molecules to treat diseases that result from dysregulation of the complement cascade. Our complement
pipeline consists of several proteases that regulate the complement cascade including CB <FONT STYLE="white-space:nowrap">2782-PEG,</FONT> a C3 degrader for the potential treatment of dry <FONT STYLE="white-space:nowrap">age-related</FONT> macular
degeneration (dAMD), improved Complement Factor I protease CB 4332 for patients with deficiencies in CFI including dAMD, and proteases from our ProTUNE<SUP STYLE="font-size:85%; vertical-align:top">&#153;</SUP> C3b/C4b degrader and ImmunoTUNE<SUP
STYLE="font-size:85%; vertical-align:top">&#153;</SUP> C3a/C5a degrader platforms designed to target other disorders of the complement or inflammatory pathways. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Forward-Looking Statements </B> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This press release contains
forward-looking statements that involve substantial risks and uncertainties. Forward-looking statements include, without limitation, those regarding potential strategic alternatives, potential markets for CB
<FONT STYLE="white-space:nowrap">2782-PEG</FONT> and CB 4332, plans for clinical development of CB <FONT STYLE="white-space:nowrap">2782-PEG</FONT> and CB 4332 in dry AMD, and the continued generation of candidates to treat diseases that result from
dysregulation of the complement cascade, as well as statements about the benefits of our protease engineering platform. Actual results or events could differ materially from the plans, intentions, expectations, and projections disclosed in the
forward-looking statements. Various important factors could cause actual results or events to differ materially, including, but not limited to, the risk that we will not identify or execute any strategic alternatives, that clinical trials and
preclinical studies may be delayed as a result of <FONT STYLE="white-space:nowrap">COVID-19,</FONT> competitive products, and other factors, that CB <FONT STYLE="white-space:nowrap">2782-PEG,</FONT> CB 4332 and the Company&#146;s complement
degraders are not yet in human clinical trials and will require clinical additional testing, including multiple clinical trials, before being approved, that the Company will need to raise additional capital, and other risks described in the
&#147;Risk Factors&#148; section of the Company&#146;s Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> filed with the Securities and Exchange Commission (the &#147;SEC&#148;) on March&nbsp;31, 2022, the Quarterly Report on Form <FONT
STYLE="white-space:nowrap">10-Q</FONT> filed with the SEC on November&nbsp;12, 2021, and in other filings filed from time to time with the SEC. The Company does not assume any obligation to update any forward-looking statements, except as required
by law. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Contact: </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Trisha Colton </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Catalyst Biosciences, Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>investors@catbio.com </U></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g313223dsp001.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Catalyst Biosciences, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Condensed Consolidated Balance Sheets </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(In thousands, except share and per share amounts) </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="74%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,&nbsp;2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,&nbsp;2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current assets:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">44,347</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">30,360</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Short-term investments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,504</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">48,994</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts receivable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,818</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,313</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid and other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,807</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,843</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">51,476</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">89,510</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Long-term investments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,543</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other assets, noncurrent</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">472</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">528</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Right-of-use</FONT></FONT>
assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,744</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,832</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Property and equipment, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">970</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">433</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">55,662</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">94,846</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Liabilities and stockholders&#146; equity</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,419</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,931</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,467</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,476</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">230</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,983</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other accrued liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,072</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,743</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,977</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">663</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14,165</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17,796</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease liability, noncurrent</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">408</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">981</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14,573</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">18,777</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stockholders&#146; equity:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Preferred stock, $0.001 par value, 5,000,000 shares authorized; zero shares issued and
outstanding</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Common stock, $0.001 par value, 100,000,000 shares authorized; 31,409,707 and 22,097,820 shares
issued and outstanding at December&nbsp;31, 2021 and 2020, respectively</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">31</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">443,752</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">390,803</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated other comprehensive income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(402,694</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(314,761</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total stockholders&#146; equity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">41,089</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">76,069</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total liabilities and stockholders&#146; equity</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">55,662</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">94,846</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g313223dsp001.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Catalyst Biosciences, Inc.</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Condensed Consolidated Statements of Operations </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(In thousands, except share and per share amounts) </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="80%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenue:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">License</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15,100</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Collaboration</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,338</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,848</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">License and collaboration revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,338</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">20,948</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cost of license</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,102</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cost of collaboration</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,380</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,061</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">68,889</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">52,975</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">18,963</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16,180</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">95,232</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">78,318</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(87,894</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(57,370</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest and other income (expense), net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(39</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,129</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(87,933</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(56,241</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss per share attributable to common stockholders, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2.87</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2.93</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Shares used to compute net loss per share attributable to common stockholders, basic and
diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">30,640,977</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19,179,299</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>5
<FILENAME>cbio-20220331.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20220115.12 -->
<!-- Creation date: 4/5/2022 1:35:07 AM Eastern Time -->
<!-- Copyright (c) 2022 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema
  xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric"
  xmlns:num="http://www.xbrl.org/dtr/type/numeric"
  xmlns:us-types="http://fasb.org/us-types/2021-01-31"
  xmlns:cbio="http://www.catalystbiosciences.com/20220331"
  xmlns:dei="http://xbrl.sec.gov/dei/2021"
  xmlns:xbrli="http://www.xbrl.org/2003/instance"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
  attributeFormDefault="unqualified"
  elementFormDefault="qualified"
  targetNamespace="http://www.catalystbiosciences.com/20220331"
  xmlns:xsd="http://www.w3.org/2001/XMLSchema">
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance" />
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2021/dei-2021.xsd" namespace="http://xbrl.sec.gov/dei/2021" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/numeric" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/non-numeric" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/naics/2021/naics-2021.xsd" namespace="http://xbrl.sec.gov/naics/2021" />
    <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="cbio-20220331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Label Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="cbio-20220331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation Links, all" xlink:type="simple" />
      <link:roleType roleURI="http://www.catalystbiosciences.com//20220331/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>6
<FILENAME>cbio-20220331_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20220115.12 -->
<!-- Creation date: 4/5/2022 1:35:07 AM Eastern Time -->
<!-- Copyright (c) 2022 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cover [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation State Country Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation State Country Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line Two</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line Two</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Written Communications</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Soliciting Material</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Issuer Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Issuer Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security 12b Title</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security 12b Title</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>7
<FILENAME>cbio-20220331_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20220115.12 -->
<!-- Creation date: 4/5/2022 1:35:07 AM Eastern Time -->
<!-- Copyright (c) 2022 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
    xmlns:link="http://www.xbrl.org/2003/linkbase"
    xmlns:xlink="http://www.w3.org/1999/xlink"
    xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
    xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
    xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.catalystbiosciences.com//20220331/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="cbio-20220331.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.catalystbiosciences.com//20220331/taxonomy/role/DocumentDocumentAndEntityInformation">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="22.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="23.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="25.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="26.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="27.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="28.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="29.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="30.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="31.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2" order="32.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="33.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="34.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="35.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="36.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="37.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_WrittenCommunications" order="38.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SolicitingMaterial" order="39.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementTenderOffer" order="40.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer" order="41.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="42.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="43.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="44.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="45.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>g313223dsp001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g313223dsp001.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M]X?_ %L&OKL%6]K1BW_5CX/,*'L,1**VN;0KL.(* "@#!U;_ )&GP\?]J?\
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M/L>A% !JVKPZQH&F7$?RR+J5NDT9X,;A^5- %G1_G^(/B,MSMBMU7V&TG^=
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MI\,B_M;);&]MW3RL^6Y((*]@?>OHL"ZL8<E6-K'B8_V4ZGM*3WW.@KT#SPH
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H ,4!L&* "@#_
!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>g313223g0405021300120.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g313223g0405021300120.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !: M # 2(  A$! Q$!_\0
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M445Z9XX4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M 4444 %%%% !1110 5#=_P#'G-_N'^535#=_\><W^X?Y5G5_AR]"H?$A\?\
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M>N* +6H:?!JFF26=PN4D7&>X/8CW%<&U]<+J>C:-?Y-Y8WRJ'QQ)'_"V:](
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ML /))SC\LU*^E12KB::>5L$!F89'0\8&!C:*<=,B9'6221R\;1%B0#M/T %
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=\: ):*** "BBB@ HHHH **** "BBB@ HHHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140141695692008">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001124105<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 31,  2022<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">CATALYST BIOSCIENCES, INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation State Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">000-51173<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">56-2020050<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">611 Gateway Blvd<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 710<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">South San Francisco<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94080<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(650)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">871-0761<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre Commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre Commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security 12b Title</a></td>
<td class="text">Common Stock<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">CBIO<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>d313223d8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2021"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="cbio-20220331.xsd" xlink:type="simple"/>
    <context id="duration_2022-03-31_to_2022-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
        </entity>
        <period>
            <startDate>2022-03-31</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <dei:AmendmentFlag contextRef="duration_2022-03-31_to_2022-03-31">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="duration_2022-03-31_to_2022-03-31"
      id="Hidden_dei_EntityCentralIndexKey">0001124105</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="duration_2022-03-31_to_2022-03-31">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="duration_2022-03-31_to_2022-03-31">2022-03-31</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="duration_2022-03-31_to_2022-03-31">CATALYST BIOSCIENCES, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="duration_2022-03-31_to_2022-03-31">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="duration_2022-03-31_to_2022-03-31">000-51173</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="duration_2022-03-31_to_2022-03-31">56-2020050</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="duration_2022-03-31_to_2022-03-31">611 Gateway Blvd</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="duration_2022-03-31_to_2022-03-31">Suite 710</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="duration_2022-03-31_to_2022-03-31">South San Francisco</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="duration_2022-03-31_to_2022-03-31">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="duration_2022-03-31_to_2022-03-31">94080</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="duration_2022-03-31_to_2022-03-31">(650)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="duration_2022-03-31_to_2022-03-31">871-0761</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="duration_2022-03-31_to_2022-03-31">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="duration_2022-03-31_to_2022-03-31">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="duration_2022-03-31_to_2022-03-31">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="duration_2022-03-31_to_2022-03-31">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="duration_2022-03-31_to_2022-03-31">Common Stock</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="duration_2022-03-31_to_2022-03-31">CBIO</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="duration_2022-03-31_to_2022-03-31">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="duration_2022-03-31_to_2022-03-31">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>12
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MX/E"*?L^<&?A\E\9P_\ 4$L#!!0    ( $*:A%2?H!OPL0(  .(,   -
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MCVG.D4*NU"P>-8?20$3;8T.P6BP^0"X99K>]9!:G<Z17B%S7G:4]VR]/06^
MKSI,<4)I2$LS#O#-TG\R]_,,-47E2B.56QIXT^7^=N!)T:$B6!::1<G3HAVE
M?QW']I#3Z:]C(K1Z6^CY<6A4"H[<8R6,<6*T_C6"R0_L?@!02P,$%     @
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M6@L5!K!O<B )+LF5&U)=Z7FFMW>3>TFH=>Y!L/?P&HT=S8\?M_P!4$L#!!0
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ML;S63AI_YHOA/UY_ 5!+ 0(4 Q0    ( $*:A%0'04UB@0   +$    0
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MB@P  'AL+W-T>6QE<RYX;6Q02P$"% ,4    " !"FH14EXJ[',     3 @
M"P              @ %F#P  7W)E;',O+G)E;'-02P$"% ,4    " !"FH14
M'#AEZC\!   \ @  #P              @ %/$   >&PO=V]R:V)O;VLN>&UL
M4$L! A0#%     @ 0IJ$5"0>FZ*M    ^ $  !H              ( !NQ$
M 'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS4$L! A0#%     @ 0IJ$5&60
M>9(9 0  SP,  !,              ( !H!(  %M#;VYT96YT7U1Y<&5S72YX
8;6Q02P4&      D "0 ^ @  ZA,

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="d313223d8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.catalystbiosciences.com//20220331/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="d313223d8k.htm">d313223d8k.htm</File>
    <File>cbio-20220331.xsd</File>
    <File>cbio-20220331_lab.xml</File>
    <File>cbio-20220331_pre.xml</File>
    <File>d313223dex101.htm</File>
    <File>d313223dex102.htm</File>
    <File>d313223dex991.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="23">http://xbrl.sec.gov/dei/2021</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>17
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "d313223d8k.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "d313223d8k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "cbio-20220331_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "cbio-20220331_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "cbio-20220331.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.sec.gov/dei/2021/dei-2021.xsd",
      "https://xbrl.sec.gov/naics/2021/naics-2021.xsd"
     ]
    }
   },
   "elementCount": 24,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2021": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 23,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "cbio",
   "nsuri": "http://www.catalystbiosciences.com/20220331",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d313223d8k.htm",
      "contextRef": "duration_2022-03-31_to_2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "100000 - Document - Document and Entity Information",
     "role": "http://www.catalystbiosciences.com//20220331/taxonomy/role/DocumentDocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d313223d8k.htm",
      "contextRef": "duration_2022-03-31_to_2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.catalystbiosciences.com//20220331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.catalystbiosciences.com//20220331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.catalystbiosciences.com//20220331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.catalystbiosciences.com//20220331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.catalystbiosciences.com//20220331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.catalystbiosciences.com//20220331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.catalystbiosciences.com//20220331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.catalystbiosciences.com//20220331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.catalystbiosciences.com//20220331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.catalystbiosciences.com//20220331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.catalystbiosciences.com//20220331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.catalystbiosciences.com//20220331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation State Country Code",
        "terseLabel": "Entity Incorporation State Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.catalystbiosciences.com//20220331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.catalystbiosciences.com//20220331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.catalystbiosciences.com//20220331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.catalystbiosciences.com//20220331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre Commencement Issuer Tender Offer",
        "terseLabel": "Pre Commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.catalystbiosciences.com//20220331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre Commencement Tender Offer",
        "terseLabel": "Pre Commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.catalystbiosciences.com//20220331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Security 12b Title",
        "terseLabel": "Security 12b Title"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.catalystbiosciences.com//20220331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.catalystbiosciences.com//20220331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.catalystbiosciences.com//20220331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.catalystbiosciences.com//20220331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications",
        "terseLabel": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.catalystbiosciences.com//20220331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>18
<FILENAME>0001193125-22-095321-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-22-095321-xbrl.zip
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MZ$7.K&O*[3D8@U*0WJV[?=!E;A%G5 UYS6^,9ST:N]@#17D/Q_[R5U@=B^F
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M\;:)YAD74M8HHBR8[1S;>=$B]!T>UC-Z*WKF+Z->WWSR JK4<RVY/I:G+\U
M2=&6SUQ):N?=\0#:[:AG6Z=^I4S#W:V+E([9 &0X*D("-I/>FWCU8G#YWO;5
MV4 V=AJN-M#-%]H ( #KNK'POKRR?7*+>&(-S9C8Y@SYT+G^3AB1*D>*U!ZS
M57P&1*/5I1LLKZCRZ3_+N/5LB*X3^HAR&7''Q-.%?NCQ"[@$IG>/3577N2+
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MF\6<U5SAC^$*9+/!^?\#4$L#!!0    ( $*:A%1+QG)@DQH  #!L   1
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M8!?4=);FM_327)<3>MBR;?/1Y?"/B88=9A* EN%M.#USD]:$[)NI8I0[64F
M/S#42 +)HRH%!LLL<7(S5" :=JE"#G6JZ6%XHM^#1Q)UG9>*O\5WQ; R8&&,
M0=F 33,\%M#J!O3\.+Z)U:P4U2QGKLX*G1=B7FA@?X;2;)"/=J>Z=_CX+)"2
M+"\C6$NALS'3LV(W(K&NG_!0,B8RX$.1PQ/A:Y$ @M:U>U)E8SE64;_G!1&^
M!@=@?XK@W\$PGA$2)4R7MV)]/E'T%;P&Q(I951B4&N 3;$A<95H6P/OD6F8E
M3/0$"):EF**7A:%!Z$8*-)Z6$NX;,ABX VPTNMX?TU+T0L2% B$7D@Q%JF/B
M+8V+6[PHKU>H#&X;D,/]'E(]5*+*D@I6CZ],5.I%;=D>/;[H'S?M4*=N$\N&
M8"QA3=.9RHPD\TBB VOZU_:+:# 8H&:(*<PU$>O_ KB G\&.RRRK %_]1R5/
M(C&3.L'G=)[H6**^X,;'<5XDQ&MB90;J)5/'37CG%HQ:"D*.XA#;;3/5\"\@
MTJE&96"2"#;SWQ7(5,(,SM,$)'I3_.GD'(@%+S[60]!V%!T)+UQK8(;34B-3
M%"0@2I,>9<@'6JK=XD*-*W@D>$]Y*TDOHP3IK-\#Z[W]C]D]7KU,32XF$K[
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M@,)LF)F,U4Z6SPLY6]M#*T)#;X  [C[%Q_><I(*%0H=@JAAU'92 <(#1\2<
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M+&Y>HDQ<Z*$3$U)"7I@7E2"1$! =Y ]$*6^4B?J].IV%B:]4%:0>Z-M(#'P
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M9*V'OF0A7NOMH9(&PWF5]ILY=GE1\EA0,N_126.KX0AL'7L)Z;P'(*OQQQ1
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M5. !-A<\(1<;@+BO(J#(.T']HAC$CTY#"2$,0T%33"7K4O3C!#T%?MO#\/"
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MXPU<9?11@F/O9RX*H1?48>#WH?,/./)]HO8GG5:D\MM;/O8TFO1D13U9B9Y
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M(6Z'*/-B"-JO0HSWC?I,F!>]7RHVZ@^\OSP>G T?)W0U:JO05;WO_$5T-<L
M;TL;6!VK<D7.%7GQ0M#2?%ZB?(0,J47@FXK>U.IZ78FA?#FI\A#E!R)0Q2>K
M9/V>HZ:UU0,B%E2BXH NXH+';Y."QVA12Z;%R9*ZV]HF2)Q0)@M(_&3N:Y*O
M22;!>MP; ;,=:LJJ3?@V)K?OF:$ 2)"NAWQ!EBW&X[M3ZHD.B&7YN%X<N@[
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M,3 R+FAT;5!+ 0(4 Q0    ( $*:A%33X?A0<!8  +KH   1
M  "  0U+  !D,S$S,C(S9&5X.3DQ+FAT;5!+!08     !P ' +X!  "L80
"   !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
